Vitae Pharmaceuticals (VTAE) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Stifel Downgrades Vitae Pharmaceuticals (VTAE) to Hold
March 4, 2016 7:13 AM ESTStifel downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Buy to Hold and removed its price target (prior $22.00).
For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.
Shares of Vitae Pharmaceuticals closed at $9.80 yesterday.
... More